The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma
Journal
Oncology (Switzerland)
Journal Volume
85
Journal Issue
5
Pages
312-316
Date Issued
2013
Author(s)
Abstract
Objectives: A germline BIM deletion polymorphism has been proposed to predict a poor treatment efficacy of certain kinase inhibitors. The current study aimed to explore whether the BIM deletion polymorphism predicts the treatment efficacy of sorafenib for advanced hepatocellular carcinoma (HCC). Methods: All patients who were enrolled in clinical trials to receive sorafenib-containing regimens as first-line therapy for advanced HCC and consented to providing peripheral blood samples were included. Polymerase chain reaction followed by gel electrophoresis was used to detect the germline BIM deletion polymorphism. Results: A total of 89 patients were enrolled; 69 (77%) patients had chronic hepatitis B infection, and 18 (20%) had chronic hepatitis C infection. The heterozygous BIM deletion polymorphism was identified in 9 (10%) patients. Patients with and without the BIM deletion polymorphism had similar response rates (11 vs. 6%) and disease control rates (56 vs. 61%). The time to progression, progression-free survival, and overall survival were similar between patients with and without the BIM deletion polymorphism. After adjusting for basic clinicopathologic variables and treatment regimens, the BIM polymorphism still could not predict treatment outcomes. Conclusions: The BIM deletion polymorphism was not associated with the treatment efficacy of sorafenib for advanced HCC. ? 2013 S. Karger AG, Basel.
SDGs
Other Subjects
BIM protein; sorafenib; adult; advanced cancer; Article; blood; blood sampling; cancer patient; chronic hepatitis; clinical article; disease control; female; gel electrophoresis; gene deletion; germline mutation; hepatitis B; hepatitis C; human; liver cell carcinoma; male; middle aged; overall survival; polymerase chain reaction; priority journal; progression free survival; treatment outcome; treatment response
Publisher
S. Karger AG
Type
journal article